Recent publications and conference presentations from VHsquared include:
November 25, 2018 – A discussion of the formulation of V565 required to provide gastro-protection and enable optimal delivery to the lower intestinal tract in monkeys was published in Drug Development and Industrial Pharmacy
PEGS Europe Protein and Antibody Engineering Summit, November 12-16 2018, Lisbon, Portugal
Oral presentation – V565 Is an Orally Administered, Protease-Resistant, Anti-TNF Domain Antibody for the Treatment of Inflammatory Bowel Disease (Contact us here for more information.)
Falk Foundation Symposium 213, October 5 – 6, Milan, Italy – Tailored Therapies for IBD: A Look into the Future
The British Society of Gastroenterology Annual Meeting 2018, June 4-7, Liverpool UK – presented as an Abstract of Distinction
11th Annual Proteins and Antibodies Congress, April 16-17 2018, London UK & 17th Annual Pep Talk, January 8-12 2018, San Diego, USA
March 21, 2018 – Preclinical research supporting use of oral anti-TNFα Vorabody V565 in IBD treatment published in Scientific Reports
First full account of V565 preclinical development available in open access journal
13th Congress of ECCO, February 14-17 2018, Vienna, Austria
2017 Antibody Engineering & Therapeutics meeting, December 10-14 2017, San Diego, USA
PEGS Europe Protein and Antibody Engineering Summit, November 13-17 2017, Lisbon, Portugal
25th United European Gastroenterology Week, Oct 28- Nov 1 2017, Barcelona, Spain
A Protease-resistant Oral Domain Antibody to TNFα Delivers High Concentrations of Active Compound in Ileal Fluid of Subjects with an Ileostomy
Oral presentation – V565, A Novel Oral Domain Antibody to TNF, Reduces Colonic Mucosal Inflammation after 7 Days Oral Dosing to Patients with Ulcerative Colitis. (Contact us here for more information.)
Oral presentation – A Novel Oral Domain Antibody to Tumour Necrosis Factor (TNF), Engineered to be Stable to Intestinal Proteases, Results in High Concentrations of Active Compound Detected in Faeces of Crohn’s Patients After Oral Dosing. (You can read the abstract, OP272 here, or contact us here for more information.)
18th International Congress of Mucosal Immunology, July 19-22 2017, Washington DC, USA
Preclinical assessment of a novel anti-TNFα Vorabody™ as an oral therapy for Crohn’s Disease
Global Conference on Pharmaceutics and Drug Delivery Systems, June 29 – July 1 2017, Valencia Spain
Oral delivery of a novel domain antibody (Vorabody™) for the treatment of Crohn’s Disease
10th Annual Proteins and Antibodies Congress, April 24-25 2017, London UK